Modulation of the Activity of the Cerebellum in Autism (MACA) (MACA)

April 4, 2023 updated by: Beatriz Catoira

Modulation of the Activity in the Cerebellum With Transcranial Direct Current Stimulation in Autistic Participants

Research on the involvement of the cerebellum in social understanding behavior and the mentalizing brain system has just begun. Knowledge about the neurobiology of social understanding is important for understanding the ways to manipulate these processes. Like cerebral tDCS, cerebellar tDCS could then be used to enhance more complex processes, such as mentalizing, in healthy individuals. It can eventually also be examined as a therapeutic tool for patients with mentalizing difficulties such as patients with ASD. In this study, it is examined whether anodal tDCS at the right posterior cerebellum influences social understanding and which cerebro-cerebellar networks play a role in this process.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Autism Spectrum Disorders (ASD) are a group of lifelong neurodevelopmental disorders characterized by social and communicative difficulties and repetitive and stereotyped behaviors. Research has shown that cerebellar abnormalities are among the most important etiological factors for ASD. The cerebellum is found to be most frequently involved in tasks where participants must remember or imagine past or future autobiographical events, judge persons or situations based on behavioral sentences, make trait inferences of others using stories, words or faces, and describe persons or objects based on behavioral or object pictures. Recent research has also provided evidence on the involvement of the posterior areas of the cerebellum in social cognition.

Specifically, the areas crus I and crus II, located at the lateral hemispheres of the posterior cerebellum, are associated with more complex cognitive and social processes, such as mentalizing. Mentalizing is the cognitive ability to attribute mental states, such as desires, intentions, and beliefs, to other people. This ability is needed to understand and predict other people's behavior and is the main component of social cognition. Problems with mentalizing, including the attribution of false beliefs to others, are characteristic for autism spectrum disorder (ASD). A sequencing task (that included social and non social conditions) showing that cerebellar patients performed worse than healthy participants.

Facial emotion recognition refers to the ability to derive emotional meaning from facial expressions and has been shown to underlie social competency. Recent literature reviews have reported significant facial emotion recognition impairments in individuals with ASD. These impairments take various forms, such as a reduced accuracy in labeling facial emotions or reduced specificity in rating facial emotions of varying intensity . Thus, there is evidence suggesting that ASD is associated with a selective impairment in facial emotion recognition.

Transcranial direct current stimulation (tDCS) is a noninvasive technique that can produce long-lasting changes in the excitability and spontaneous activity of the stimulated brain areas. Therefore, tDCS is investigated as a possible treatment for different psychiatric diseases. Cerebellar tDCS have shown to also produce prolonged changes successfully at the neural and behavioral level. However, due to the high density of neurons in the cerebellum and diffuse connections to the cerebrum, it is more difficult to understand the working mechanisms of cerebellar as compared to cerebral tDCS. In addition, the electrical current will spread across more neurons in the cerebellum by cerebellar tDCS and will functionally affect the cerebral regions to which these cerebellar neurons are connected as well. Therefore, the type of behavioral effect, such as an improvement of performance after anodal tDCS or an impairment of performance after cathodal tDCS, is harder to predict for cerebellar than cerebral tDCS.

Modulation of social understanding with tDCS has been studied by stimulating the key mentalizing regions mPFC and TPJ. In healthy participants, an improvement on tasks was found that required the enhancement or inhibition of representation of the self or of others, which is important for mentalizing, after anodal tDCS at the TPJ compared to sham tDCS or cathodal tDCS. The effect of cerebellar tDCS on social understanding using action sequences has not yet been examined.

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Brussels
      • Jette, Brussels, Belgium, 1090

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Participant Inclusion/exclusion criteria:

  • Participants must be more than 18 years old
  • normal eyesight and hearing;
  • Dutch, French or English speaking;

Neurotypical participants inclusion/exclusion criteria:

  • No disorder (now or in the past) that could have affected the brain such as cerebrovascular accidents (CVA), neurodegenerative disorders, or essential tremor;
  • No neurological diseases that could affect reasoning or intellectual abilities (such as Parkinson's Disease, Epilepsy, and Multiple Sclerosis)
  • Neurotypical participants will be matched on age and gender to the ASD population;

ASD participants inclusion/exclusion criteria:

Patients with a formal diagnosis of high-functioning ASD as determined by the clinical psychologist/psychiatrist.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ASD_anodalstimulation
ASD participant, anodal stimulation on the first session, sham stimulation on the second sesion
Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
Sham Comparator: ASD_shamstimulation
ASD participant, sham stimulation on the first session, anodal stimulation on the second sesion
Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
Active Comparator: NT_anodalstimulation
Neurotypical participant, anodal stimulation on the first session, sham stimulation on the second sesion
Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
Sham Comparator: NT_shamstimulation
Neurotypical participant, sham stimulation on the first session, anodal stimulation on the second sesion
Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
Active Comparator: H-AQ_anodalstimulation
non diagnosed autistic participant,anodal stimulation on the first session, sham stimulation on the second sesion
Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
Sham Comparator: H-AQ_shamstimulation
non diagnosed autistic participant, sham stimulation on the first session, anodal stimulation on the second sesion
Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PS_RT
Time Frame: assessment will begin 10 minutes after stimulation and last up to 15 minutes
Reaction Time in the pictorial sequencing time
assessment will begin 10 minutes after stimulation and last up to 15 minutes
PS_accuracy
Time Frame: assessment will begin 10 minutes after stimulation and last up to 15 minutes
Accuracy in the pictorial sequencing task
assessment will begin 10 minutes after stimulation and last up to 15 minutes
ER_RT
Time Frame: assessment will begin 20 minutes after stimulation and last up to 5 minutes
Reaction Times in the emotion recognition task
assessment will begin 20 minutes after stimulation and last up to 5 minutes
ER_accuracy
Time Frame: assessment will begin 20 minutes after stimulation and last up to 5 minutes
Accuracy in the emotion recognition task
assessment will begin 20 minutes after stimulation and last up to 5 minutes
Brain activity at the emotion recognition task
Time Frame: assessment will begin 20 minutes after stimulation and last up to 5 minutes
Brain activity (fMRI) in regions of interest/whole brain analysis. Differences between stimulation and sham, between task conditions and between sessions as well as possible interactions in between those factors and covariates (AQ scores, age, gender...)
assessment will begin 20 minutes after stimulation and last up to 5 minutes
Brain activity at resting state
Time Frame: assesment will begin concurrent with stimulation and last up to 20 minutes
Brain activity (fMRI) in regions of interest/whole brain analysis. Differences between stimulation and sham, between task conditions and between sessions as well as possible interactions in between those factors and covariates (AQ scores, age, gender...)
assesment will begin concurrent with stimulation and last up to 20 minutes
Brain activity at the pictorial sequencing task
Time Frame: assessment will begin 10 minutes after stimulation and last up to 15 minutes
Brain activity (fMRI) in regions of interest/whole brain analysis. Differences between stimulation and sham, between task conditions and between sessions as well as possible interactions in between those factors and covariates (AQ scores, age, gender...)
assessment will begin 10 minutes after stimulation and last up to 15 minutes
White matter integrity in the cerebellum
Time Frame: assessment will begin immediately after stimulation and last up to 10 minutes
White matter integrity matrix (FA, MD, RD) in the cerebellum using tract-based spatial statistics in the cerebellum & differences between groups
assessment will begin immediately after stimulation and last up to 10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Connectivity_PStask
Time Frame: assessment will begin 10 minutes after stimulation and last up to 15 minutes
Brain connectivity (fMRI) analysis on the pictorial sequencing task
assessment will begin 10 minutes after stimulation and last up to 15 minutes
Connectivity_ERtask
Time Frame: assessment will begin 20 minutes after stimulation and last up to 5 minutes
Brain connectivity (fMRI) analysis on the emotion recognition task
assessment will begin 20 minutes after stimulation and last up to 5 minutes
Connectivity_stimulation
Time Frame: assesment will begin concurrent with stimulation and last up to 20 minutes
Brain connectivity (fMRI) analysis during stimulation
assesment will begin concurrent with stimulation and last up to 20 minutes
Fiber tractography between the cerebellum and the default mode/ mentalizing network
Time Frame: assessment will begin immediately after stimulation and last up to 10 minutes
Fiber tractography (Diffusion weighted imaging) between the cerebellum and the default mode / mentalizing network, by extraction of white matter integrity parameters on each fiber tract
assessment will begin immediately after stimulation and last up to 10 minutes
ROI-based structural connectivity
Time Frame: assessment will begin immediately after stimulation and last up to 10 minutes
Structural connectivity (DWI) between ROIs from the default mode/mentalizing network
assessment will begin immediately after stimulation and last up to 10 minutes
Whole brain structural network construction
Time Frame: assessment will begin immediately after stimulation and last up to 10 minutes
Structural connectivity (DWI) within the whole brain using graph theory
assessment will begin immediately after stimulation and last up to 10 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electrical Field Simulations
Time Frame: First 10 minutes of assessment
Simulation of the electric field generated by the tDCS stimulation.
First 10 minutes of assessment
Correlations between DWI, behavioural data, simulation and functional data
Time Frame: assessment will include data from the 60 minutes that are spent in the scanner in the session
The primary outcome measures from the diffusion weighted imaging will provide different measures for structural connectivity per participant. The correlation of these measures with behavioural and/or functional data will be computed.
assessment will include data from the 60 minutes that are spent in the scanner in the session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 24, 2022

Primary Completion (Anticipated)

March 1, 2024

Study Completion (Anticipated)

October 30, 2024

Study Registration Dates

First Submitted

December 6, 2022

First Submitted That Met QC Criteria

March 20, 2023

First Posted (Actual)

March 23, 2023

Study Record Updates

Last Update Posted (Actual)

April 7, 2023

Last Update Submitted That Met QC Criteria

April 4, 2023

Last Verified

April 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on tDCS

Subscribe